NEUROCRINE BIOSCIENCES INC (1NBIX.MI) Stock Fundamental Analysis
Europe - Euronext Milan - BIT:1NBIX - US64125C1099 - Common Stock
125.4 EUR
-9.95 (-7.35%)
Taking everything into account, 1NBIX scores 7 out of 10 in our fundamental rating. 1NBIX was compared to 82 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making 1NBIX a very profitable company, without any liquidiy or solvency issues. 1NBIX is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! These ratings would make 1NBIX suitable for growth and quality investing!
1. Profitability
1.1 Basic Checks
1NBIX had positive earnings in the past year.
1NBIX had a positive operating cash flow in the past year.
In the past 5 years 1NBIX has always been profitable.
In the past 5 years 1NBIX always reported a positive cash flow from operatings.
1.2 Ratios
1NBIX has a Return On Assets of 10.03%. This is amongst the best in the industry. 1NBIX outperforms 81.71% of its industry peers.
1NBIX has a better Return On Equity (14.25%) than 81.71% of its industry peers.
With an excellent Return On Invested Capital value of 11.10%, 1NBIX belongs to the best of the industry, outperforming 85.37% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for 1NBIX is in line with the industry average of 12.14%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 10.03% | ||
| ROE | 14.25% | ||
| ROIC | 11.1% |
ROA(3y)7.79%
ROA(5y)10.24%
ROE(3y)11.14%
ROE(5y)15.22%
ROIC(3y)11.4%
ROIC(5y)11.57%
1.3 Margins
Looking at the Profit Margin, with a value of 15.95%, 1NBIX is in the better half of the industry, outperforming 79.27% of the companies in the same industry.
1NBIX's Profit Margin has improved in the last couple of years.
1NBIX has a Operating Margin of 20.64%. This is amongst the best in the industry. 1NBIX outperforms 82.93% of its industry peers.
In the last couple of years the Operating Margin of 1NBIX has declined.
The Gross Margin of 1NBIX (98.37%) is better than 96.34% of its industry peers.
1NBIX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.64% | ||
| PM (TTM) | 15.95% | ||
| GM | 98.37% |
OM growth 3Y10.53%
OM growth 5Y-2.95%
PM growth 3Y22.39%
PM growth 5Y25.28%
GM growth 3Y-0.06%
GM growth 5Y-0.1%
2. Health
2.1 Basic Checks
1NBIX has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for 1NBIX has been increased compared to 1 year ago.
The number of shares outstanding for 1NBIX has been increased compared to 5 years ago.
1NBIX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
1NBIX has an Altman-Z score of 8.51. This indicates that 1NBIX is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 8.51, 1NBIX belongs to the top of the industry, outperforming 84.15% of the companies in the same industry.
1NBIX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 8.51 |
ROIC/WACC1.27
WACC8.75%
2.3 Liquidity
A Current Ratio of 3.38 indicates that 1NBIX has no problem at all paying its short term obligations.
1NBIX has a better Current ratio (3.38) than 65.85% of its industry peers.
1NBIX has a Quick Ratio of 3.27. This indicates that 1NBIX is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 3.27, 1NBIX is doing good in the industry, outperforming 68.29% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.38 | ||
| Quick Ratio | 3.27 |
3. Growth
3.1 Past
1NBIX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.06%, which is quite good.
1NBIX shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 58.39% yearly.
1NBIX shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 19.61%.
Measured over the past years, 1NBIX shows a very strong growth in Revenue. The Revenue has been growing by 24.48% on average per year.
EPS 1Y (TTM)12.06%
EPS 3Y35.58%
EPS 5Y58.39%
EPS Q2Q%64.52%
Revenue 1Y (TTM)19.61%
Revenue growth 3Y27.61%
Revenue growth 5Y24.48%
Sales Q2Q%27.78%
3.2 Future
Based on estimates for the next years, 1NBIX will show a very strong growth in Earnings Per Share. The EPS will grow by 35.05% on average per year.
1NBIX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.49% yearly.
EPS Next Y53.46%
EPS Next 2Y44.8%
EPS Next 3Y36.99%
EPS Next 5Y35.05%
Revenue Next Year21.48%
Revenue Next 2Y19.74%
Revenue Next 3Y15.88%
Revenue Next 5Y12.49%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 35.13, 1NBIX can be considered very expensive at the moment.
Based on the Price/Earnings ratio, 1NBIX is valued a bit cheaper than 75.61% of the companies in the same industry.
1NBIX is valuated rather expensively when we compare the Price/Earnings ratio to 26.61, which is the current average of the S&P500 Index.
1NBIX is valuated rather expensively with a Price/Forward Earnings ratio of 21.29.
Based on the Price/Forward Earnings ratio, 1NBIX is valued cheaply inside the industry as 82.93% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 24.01, 1NBIX is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 35.13 | ||
| Fwd PE | 21.29 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, 1NBIX is valued a bit cheaper than the industry average as 73.17% of the companies are valued more expensively.
80.49% of the companies in the same industry are more expensive than 1NBIX, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 24.56 | ||
| EV/EBITDA | 21.73 |
4.3 Compensation for Growth
1NBIX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of 1NBIX may justify a higher PE ratio.
1NBIX's earnings are expected to grow with 36.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.66
PEG (5Y)0.6
EPS Next 2Y44.8%
EPS Next 3Y36.99%
5. Dividend
5.1 Amount
No dividends for 1NBIX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIT:1NBIX (12/19/2025, 7:00:00 PM)
125.4
-9.95 (-7.35%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners100.77%
Inst Owner ChangeN/A
Ins Owners1.01%
Ins Owner ChangeN/A
Market Cap12.44B
Revenue(TTM)2.68B
Net Income(TTM)428.00M
Analysts84.57
Price Target148.88 (18.72%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.55%
Min EPS beat(2)7%
Max EPS beat(2)26.1%
EPS beat(4)2
Avg EPS beat(4)-22.42%
Min EPS beat(4)-85.62%
Max EPS beat(4)26.1%
EPS beat(8)3
Avg EPS beat(8)-23.05%
EPS beat(12)4
Avg EPS beat(12)-75.32%
EPS beat(16)4
Avg EPS beat(16)-76.53%
Revenue beat(2)2
Avg Revenue beat(2)3.84%
Min Revenue beat(2)3.28%
Max Revenue beat(2)4.39%
Revenue beat(4)2
Avg Revenue beat(4)1.34%
Min Revenue beat(4)-2.16%
Max Revenue beat(4)4.39%
Revenue beat(8)4
Avg Revenue beat(8)1.12%
Revenue beat(12)6
Avg Revenue beat(12)0.97%
Revenue beat(16)9
Avg Revenue beat(16)1.1%
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)3.53%
EPS NQ rev (3m)N/A
EPS NY rev (1m)11.4%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)2.3%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)2.39%
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 35.13 | ||
| Fwd PE | 21.29 | ||
| P/S | 5.43 | ||
| P/FCF | 24.56 | ||
| P/OCF | 22.87 | ||
| P/B | 4.85 | ||
| P/tB | 4.91 | ||
| EV/EBITDA | 21.73 |
EPS(TTM)3.57
EY2.85%
EPS(NY)5.89
Fwd EY4.7%
FCF(TTM)5.11
FCFY4.07%
OCF(TTM)5.48
OCFY4.37%
SpS23.09
BVpS25.86
TBVpS25.55
PEG (NY)0.66
PEG (5Y)0.6
Graham Number45.57
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 10.03% | ||
| ROE | 14.25% | ||
| ROCE | 15.26% | ||
| ROIC | 11.1% | ||
| ROICexc | 16.02% | ||
| ROICexgc | 16.25% | ||
| OM | 20.64% | ||
| PM (TTM) | 15.95% | ||
| GM | 98.37% | ||
| FCFM | 22.11% |
ROA(3y)7.79%
ROA(5y)10.24%
ROE(3y)11.14%
ROE(5y)15.22%
ROIC(3y)11.4%
ROIC(5y)11.57%
ROICexc(3y)30.35%
ROICexc(5y)27.29%
ROICexgc(3y)31.58%
ROICexgc(5y)28.03%
ROCE(3y)15.68%
ROCE(5y)15.92%
ROICexgc growth 3Y35.59%
ROICexgc growth 5Y-0.37%
ROICexc growth 3Y34.3%
ROICexc growth 5Y-0.94%
OM growth 3Y10.53%
OM growth 5Y-2.95%
PM growth 3Y22.39%
PM growth 5Y25.28%
GM growth 3Y-0.06%
GM growth 5Y-0.1%
F-Score5
Asset Turnover0.63
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 147.14% | ||
| Cap/Sales | 1.63% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 109.17% | ||
| Profit Quality | 138.57% | ||
| Current Ratio | 3.38 | ||
| Quick Ratio | 3.27 | ||
| Altman-Z | 8.51 |
F-Score5
WACC8.75%
ROIC/WACC1.27
Cap/Depr(3y)126.53%
Cap/Depr(5y)144.2%
Cap/Sales(3y)1.41%
Cap/Sales(5y)1.47%
Profit Quality(3y)172.36%
Profit Quality(5y)166.13%
High Growth Momentum
Growth
EPS 1Y (TTM)12.06%
EPS 3Y35.58%
EPS 5Y58.39%
EPS Q2Q%64.52%
EPS Next Y53.46%
EPS Next 2Y44.8%
EPS Next 3Y36.99%
EPS Next 5Y35.05%
Revenue 1Y (TTM)19.61%
Revenue growth 3Y27.61%
Revenue growth 5Y24.48%
Sales Q2Q%27.78%
Revenue Next Year21.48%
Revenue Next 2Y19.74%
Revenue Next 3Y15.88%
Revenue Next 5Y12.49%
EBIT growth 1Y-5.9%
EBIT growth 3Y41.04%
EBIT growth 5Y20.8%
EBIT Next Year2.32%
EBIT Next 3Y23.13%
EBIT Next 5Y19.04%
FCF growth 1Y54.17%
FCF growth 3Y33.71%
FCF growth 5Y32.31%
OCF growth 1Y55.54%
OCF growth 3Y32.41%
OCF growth 5Y31.38%
NEUROCRINE BIOSCIENCES INC / 1NBIX.MI FAQ
What is the fundamental rating for 1NBIX stock?
ChartMill assigns a fundamental rating of 7 / 10 to 1NBIX.MI.
What is the valuation status of NEUROCRINE BIOSCIENCES INC (1NBIX.MI) stock?
ChartMill assigns a valuation rating of 6 / 10 to NEUROCRINE BIOSCIENCES INC (1NBIX.MI). This can be considered as Fairly Valued.
How profitable is NEUROCRINE BIOSCIENCES INC (1NBIX.MI) stock?
NEUROCRINE BIOSCIENCES INC (1NBIX.MI) has a profitability rating of 8 / 10.
Can you provide the financial health for 1NBIX stock?
The financial health rating of NEUROCRINE BIOSCIENCES INC (1NBIX.MI) is 8 / 10.
Can you provide the expected EPS growth for 1NBIX stock?
The Earnings per Share (EPS) of NEUROCRINE BIOSCIENCES INC (1NBIX.MI) is expected to grow by 53.46% in the next year.